Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RZ Announces First Quarter Financial Results
Date : 05/11/2009 @ 7:05PM
http://ih.advfn.com/p.php?pid=nmona&cb=1242484625&article=37673281&symbol=NY^RZ
Sunrise Reports Financial Results for First-Quarter 2009
Date : 05/08/2009 @ 7:00AM
Source : PR Newswire
Stock : Sunrise Senior Living (SRZ)
http://ih.advfn.com/p.php?pid=nmona&cb=1242480021&article=37632120&symbol=NY%5ESRZ
MCLEAN, Va., May 8 /PRNewswire-FirstCall/ -- Sunrise Senior Living, Inc. (NYSE:SRZ) today reported financial results and operating data for the first quarter of 2009. Sunrise will host a conference call and webcast Friday, May 8, 2009, at 9:00 a.m. ET, to discuss the financial results.
"We are pleased with our restructuring efforts and the steps we have taken to date to put the company on more solid footing," said Mark Ordan, Sunrise's chief executive officer. "We remain especially focused on strengthening our core business, selling cash-draining non-core assets, eliminating non-core activities, shoring up our liquidity, and securing additional capital. Throughout our restructuring efforts, we have never, and will never, make decisions that take away from our mission or the seniors we serve as we move toward profitability."
Financial Results for First-Quarter 2009
Sunrise reported revenues of $404.4 million for the first quarter of 2009, as compared to $413.5 million for the first quarter of 2008. Net loss for the first quarter of 2009 was ($18.2) million, or ($0.36) per fully diluted share, as compared to net loss of ($33.1) million, or ($0.66) per fully diluted share, for the first quarter of 2008. The loss before income taxes and discontinued operations for the first quarter of 2009 was ($35.7) million as compared to loss before income taxes and discontinued operations for the first quarter of 2008 of ($39.2) million. The operations of Sunrise's former hospice subsidiary (which ceased operations in December 31, 2008) and the operations of Sunrise's Greystone subsidiary (which was sold on March 18, 2009) are reported as discontinued operations. During the first quarter of 2009, Sunrise recorded net income from discontinued operations of $14.0 million primarily from the sale of Greystone.
Also during the first quarter of 2009, a venture in which Sunrise is a 20-percent member, sold three of its UK communities to a venture in which Sunrise has a 10-percent interest. As a result of these sales, Sunrise recorded its share in earnings of $19.0 million.
...
Stocks in focus for Monday ( May 18,2009 )
http://www.marketwatch.com/story/stocks-in-focus-for-monday-20095160100
The week's top Personal Finance stories
( for the week of May 11-5 )
http://www.marketwatch.com/story/the-weeks-10-best-personal-finance-stories-20095168100
Dollar tugged by euro-zone GDP, Japan data rebound
http://www.marketwatch.com/story/yen-climbs-to-two-month-highs
BEWARE of OTCBB / PINK -
...once our "favorites"
<< IMO >>
GERS - PUMP AND DUMP
SWVLE - ONLY LIES, CEO needed only the money of the shareholders
GLCC & MONA - same story, only PUMP AND DUMP
UVSEE & AAGH - what a SCAM
>>>>> therefore:
Change of Rules ( JAN/2009 )
New Stocks must be NASDAQ, NYSE or AMEX
NO more OTC / PINKIES
JGBO - Quarterly report
For the quarterly period ended: March 31, 2009
http://www.sec.gov/Archives/edgar/data/1091164/000114420409027483/v149760_10q.htm
- added some stuff (LINK's) to ibox
and removed old OTCBB/PINK (once posted picks)
...feel free to personal marked me
COIN -
Converted Organics Named Lead Technology Partner in Waste-to-Fertilizer Sector for the WSA
Date : 05/15/2009 @ 9:55AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242396307&article=37749179&symbol=N^COIN
Converted Organics Inc. (NASDAQ:COIN) announced today that it has been named as the Lead Technology Partner of the World Sports Alliance (WSA) International Business Consortium (WSAIBC) For the Joint Development of the WSA Public-Private partnership Programs in the Specific Sector of Waste-to-Fertilizer (WTF).
The World Sports Alliance is an intergovernmental organization (IGO) created through a private initiative in support of the United Nations Millennium Project and its Development Goals. The WSA is headquartered at the UN Plaza in New York City and has 24 member states.
"The selection of our technology by the WSA is a very positive development for Converted Organics. The first Member State of the WSA in the program has proposed the delivery of 10 individual fertilizer production units at a price of $2.25 million per unit. We have selected Control & Power Systems, Inc.(CPS) of Fairfield, NJ to design, engineer, and fabricate the small scale units for the first proposal from the WSA,” said Jack Walsdorf, Vice President of Converted Organics for Waste Management. “The overseas market for this type of equipment is exciting. Our relationship with the WSA will highlight our technology to all 24 Member States of the WSA and other groups who are made aware of COIN thru the WSA program,” said Jack Walsdorf.
RZ -
* Raser Technologies’ Plant Named Geothermal Power Plant of the Year
Date : 05/14/2009 @ 2:43PM
http://ih.advfn.com/p.php?pid=nmona&cb=1242390003&article=37731484&symbol=NY^RZ
* Raser Technologies, Inc. Announces First Quarter Financial Results
Date : 05/11/2009 @ 7:05PM
http://ih.advfn.com/p.php?pid=nmona&cb=1242390003&article=37673281&symbol=NY^RZ
YGE -
* Yingli Green Energy Enters Into Exclusive Supplier Framework Agreement with AES Solar
Date : 05/15/2009 @ 6:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242390003&article=37740789&symbol=NY^YGE
* Yingli Green Energy to Announce First Quarter 2009 Financial Results on May 22, 2009
Date : 05/13/2009 @ 6:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242390003&article=37698301&symbol=NY^YGE
* Yingli Green Energy Becomes the First China-Based Company to Join PV CYCLE
Date : 05/11/2009 @ 7:03AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242390003&article=37659929&symbol=NY^YGE
HIG -
* The Hartford Receives Preliminary Approval For $3.4 Billion Participation In Treasury’s Capital Purchase Program
Date : 05/14/2009 @ 7:05PM
http://ih.advfn.com/p.php?pid=nmona&cb=1242388585&article=37735639&symbol=NY^HIG
http://www.bloomberg.com/apps/news?pid=20601084&sid=aQvC1rO6kRbI&refer=stocks
CTIC -
* Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
Date : 05/15/2009 @ 1:00AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242388750&article=37736352&symbol=N^CTIC
* Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
Date : 05/15/2009 @ 1:30AM
http://ih.advfn.com/p.php?pid=nmona&cb=1242388750&article=37736384&symbol=N^CTIC
GNW leads life insurance stocks rally
http://www.finanznachrichten.de/nachrichten-2009-05/13915861-genworth-leads-life-insurance-stocks-rally-020.htm
14.05.2009 21:56
Genworth leads life insurance stocks rally
NEW YORK, May 14 (Reuters) - Shares of Genworth Financial (News), a provider of mortgage and life insurance, led a rally in U.S. life insurance stocks on Thursday.
Raymond James, in a research report, said it was raising its 12-month share target price for Genworth to $5.50 from $3, citing strength in the company's U.S. retirement and protection business.
Analyst Steven Schwartz said he also expected price appreciation for shares across the sector.
Shares of Genworth rose as much as 26 percent, followed by Hartford Financial, as much as 22 percent higher, and Lincoln National, which rose 16 percent in intra-day trading on Friday.
Life insurers have been broadly hurt in recent months by weaker financial markets, which have cut into investment returns and incurred higher costs for annuity products that are impacted when market values fall.
The Dow Jones U.S. Life Insurance Index has fallen by more than half in the last 12 months, according to Reuters data.
The index rallied more than 7 percent on Thursday.
In late trading Genworth was up 17.4 percent at $4.87 after touching $5.24 earlier in the session; Hartford's stock was also up more than 17 percent at $14.75 off a day high of $15.37; and Lincoln's stock was up 11.5 percent at $16.09, after reaching $16.76 earlier in the day.
(Reporting by Lilla Zuill) Keywords: LIFEINSURANCE/STOCKS
(lilla.zuill@thomsonreuters.com;+1 646 223 6281)
COPYRIGHT
Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
PWAV -
http://shortsqueeze.com/?symbol=pwav&submit=Short+Quote%99
Shares Float 130,330,000
Total Shares Outstanding 131,978,122
% Owned by Insiders 6.73 %
% Owned by Institutions 78.70 %
Powerwave Named Finalist in TechAmerica High-Tech Innovation Awards
http://ih.advfn.com/p.php?pid=nmona&cb=1242331233&article=37607927&symbol=N%5EPWAV
Powerwave to Present at Upcoming Investor Conference
http://ih.advfn.com/p.php?pid=nmona&cb=1242331233&article=37708146&symbol=N%5EPWAV
..._bbb_ on "vacation"
( posting privileges have been suspended until 6/13/2009 3:15:31 PM Eastern )
_bbb_is on business trip in ihub-prison LOL
GNBT
http://finance.yahoo.com/news/Generex-Launches-Commercial-pz-15241489.html
Generex Launches Commercial Sales of Oral Insulin in Lebanon
Lebanese Minister of Health Spoke At Launch of Needle-Free Generex Oral-lyn(tm)
On Thursday May 14, 2009, 8:00 am EDT
WORCESTER, Mass. and BEIRUT, Lebanon, May 14, 2009 (GLOBE NEWSWIRE) -- At a press conference earlier today in Beirut, with Lebanese Minister of Health H.E. Muhammad Jawad Khalifah, Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with Benta s.a.l. (http://www.bpi.com.lb), the Company's importation, marketing, distribution and sales sub-licensee in Lebanon, announced the launch of commercial retail sales of Generex Oral-lyn(tm) in Lebanon. The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and will be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes in Lebanon.
Generex Oral-lyn(tm), Generex's proprietary oral insulin spray product, is the first non-injectable insulin approved in Lebanon. Generex Oral-lyn(tm) is delivered via the Company's proprietary RapidMist(tm) device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not reach the lungs.
The launch of Generex Oral-lyn(tm) took place at Le Royal Hotel, Dbayeh. In addition to more than 150 endocrinologists and other healthcare providers in attendance, notable participants included:
H.E. Dr. Mohamad Jawad Khalifah, Minister of Health, Lebanon
Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l.
Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and
Business Development, Generex Biotechnology Corporation
Professor Paolo Pozzilli, Head of the Department of Diabetes
and Endocrinology, University Campus Bio-Medico, Rome, Italy
Professor Sami Azar, M.D., FACP, The Department of Internal
Medicine (Endocrinology), Faculty of Medicine, American
University of Beirut -- Medical Center, Beirut, Lebanon
``It is with great enthusiasm that we launch Generex Oral-lyn(tm) in Lebanon alongside Benta s.a.l., known for their leading edge innovation,' said Anna Gluskin, Generex's Chairman & Chief Executive Officer. ``We anticipate that our truly innovative product will be well received and expand further into the Middle East over the coming year as we pursue our regulatory program.'
GNBT
http://finance.yahoo.com/news/Generex-Launches-Commercial-pz-15241489.html
Generex Launches Commercial Sales of Oral Insulin in Lebanon
Lebanese Minister of Health Spoke At Launch of Needle-Free Generex Oral-lyn(tm)
On Thursday May 14, 2009, 8:00 am EDT
WORCESTER, Mass. and BEIRUT, Lebanon, May 14, 2009 (GLOBE NEWSWIRE) -- At a press conference earlier today in Beirut, with Lebanese Minister of Health H.E. Muhammad Jawad Khalifah, Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with Benta s.a.l. (http://www.bpi.com.lb), the Company's importation, marketing, distribution and sales sub-licensee in Lebanon, announced the launch of commercial retail sales of Generex Oral-lyn(tm) in Lebanon. The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and will be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes in Lebanon.
Generex Oral-lyn(tm), Generex's proprietary oral insulin spray product, is the first non-injectable insulin approved in Lebanon. Generex Oral-lyn(tm) is delivered via the Company's proprietary RapidMist(tm) device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not reach the lungs.
The launch of Generex Oral-lyn(tm) took place at Le Royal Hotel, Dbayeh. In addition to more than 150 endocrinologists and other healthcare providers in attendance, notable participants included:
H.E. Dr. Mohamad Jawad Khalifah, Minister of Health, Lebanon
Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l.
Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and
Business Development, Generex Biotechnology Corporation
Professor Paolo Pozzilli, Head of the Department of Diabetes
and Endocrinology, University Campus Bio-Medico, Rome, Italy
Professor Sami Azar, M.D., FACP, The Department of Internal
Medicine (Endocrinology), Faculty of Medicine, American
University of Beirut -- Medical Center, Beirut, Lebanon
``It is with great enthusiasm that we launch Generex Oral-lyn(tm) in Lebanon alongside Benta s.a.l., known for their leading edge innovation,' said Anna Gluskin, Generex's Chairman & Chief Executive Officer. ``We anticipate that our truly innovative product will be well received and expand further into the Middle East over the coming year as we pursue our regulatory program.'
GNBT
http://finance.yahoo.com/news/Generex-Launches-Commercial-pz-15241489.html
Generex Launches Commercial Sales of Oral Insulin in Lebanon
Lebanese Minister of Health Spoke At Launch of Needle-Free Generex Oral-lyn(tm)
On Thursday May 14, 2009, 8:00 am EDT
WORCESTER, Mass. and BEIRUT, Lebanon, May 14, 2009 (GLOBE NEWSWIRE) -- At a press conference earlier today in Beirut, with Lebanese Minister of Health H.E. Muhammad Jawad Khalifah, Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with Benta s.a.l. (http://www.bpi.com.lb), the Company's importation, marketing, distribution and sales sub-licensee in Lebanon, announced the launch of commercial retail sales of Generex Oral-lyn(tm) in Lebanon. The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and will be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes in Lebanon.
Generex Oral-lyn(tm), Generex's proprietary oral insulin spray product, is the first non-injectable insulin approved in Lebanon. Generex Oral-lyn(tm) is delivered via the Company's proprietary RapidMist(tm) device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not reach the lungs.
The launch of Generex Oral-lyn(tm) took place at Le Royal Hotel, Dbayeh. In addition to more than 150 endocrinologists and other healthcare providers in attendance, notable participants included:
H.E. Dr. Mohamad Jawad Khalifah, Minister of Health, Lebanon
Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l.
Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and
Business Development, Generex Biotechnology Corporation
Professor Paolo Pozzilli, Head of the Department of Diabetes
and Endocrinology, University Campus Bio-Medico, Rome, Italy
Professor Sami Azar, M.D., FACP, The Department of Internal
Medicine (Endocrinology), Faculty of Medicine, American
University of Beirut -- Medical Center, Beirut, Lebanon
``It is with great enthusiasm that we launch Generex Oral-lyn(tm) in Lebanon alongside Benta s.a.l., known for their leading edge innovation,' said Anna Gluskin, Generex's Chairman & Chief Executive Officer. ``We anticipate that our truly innovative product will be well received and expand further into the Middle East over the coming year as we pursue our regulatory program.'
GNBT
http://finance.yahoo.com/news/Generex-Launches-Commercial-pz-15241489.html
Generex Launches Commercial Sales of Oral Insulin in Lebanon
Lebanese Minister of Health Spoke At Launch of Needle-Free Generex Oral-lyn(tm)
On Thursday May 14, 2009, 8:00 am EDT
WORCESTER, Mass. and BEIRUT, Lebanon, May 14, 2009 (GLOBE NEWSWIRE) -- At a press conference earlier today in Beirut, with Lebanese Minister of Health H.E. Muhammad Jawad Khalifah, Generex Biotechnology Corporation (NasdaqCM:GNBT - News) (http://www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with Benta s.a.l. (http://www.bpi.com.lb), the Company's importation, marketing, distribution and sales sub-licensee in Lebanon, announced the launch of commercial retail sales of Generex Oral-lyn(tm) in Lebanon. The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and will be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes in Lebanon.
Generex Oral-lyn(tm), Generex's proprietary oral insulin spray product, is the first non-injectable insulin approved in Lebanon. Generex Oral-lyn(tm) is delivered via the Company's proprietary RapidMist(tm) device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn(tm) does not reach the lungs.
The launch of Generex Oral-lyn(tm) took place at Le Royal Hotel, Dbayeh. In addition to more than 150 endocrinologists and other healthcare providers in attendance, notable participants included:
H.E. Dr. Mohamad Jawad Khalifah, Minister of Health, Lebanon
Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l.
Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and
Business Development, Generex Biotechnology Corporation
Professor Paolo Pozzilli, Head of the Department of Diabetes
and Endocrinology, University Campus Bio-Medico, Rome, Italy
Professor Sami Azar, M.D., FACP, The Department of Internal
Medicine (Endocrinology), Faculty of Medicine, American
University of Beirut -- Medical Center, Beirut, Lebanon
``It is with great enthusiasm that we launch Generex Oral-lyn(tm) in Lebanon alongside Benta s.a.l., known for their leading edge innovation,'' said Anna Gluskin, Generex's Chairman & Chief Executive Officer. ``We anticipate that our truly innovative product will be well received and expand further into the Middle East over the coming year as we pursue our regulatory program.''
...fxxxing shorts today all markets...
COIN - in at 1,59€ (~$2.16)
...PLI (L=low)
wow - after R/S -99,90% !!!
...ohne Worte!
(jetzt ist die Sch... nicht mal mehr den Kaugummi wert)
BKUNA ...in at 0,83€ (~ $1.13)
...me too (46 now)!
what a xxxx
?? when will we see the next one ?? within 6 month !??
ANPI !!
Angiotech and Boston Scientific welcome journal article noting important differences between drug-eluting stent brands
11.05.2009 22:46
http://www.finanznachrichten.de/nachrichten-2009-05/13876701-angiotech-and-boston-scientific-welcome-journal-article-noting-important-differences-between-drug-eluting-stent-brands-008.htm
VANCOUVER, May 11 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, (News) Inc. today announced its corporate partner, Boston Scientific Corporation, (News) has welcomed the publication of an article in the current edition of the Journal of the American College of Cardiology (JACC) reviewing data on more than 19,000 patients from the Swedish national registry who were evaluated for restenosis, or the re-narrowing or arteries after percutaneous coronary intervention (PCI). The article reported that patients who received a TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent had numerically lower incidences of repeat procedures to treat restenosis at two years as compared to patients treated with 'olimus-based drug-eluting stents (DES), including Cordis' Cypher(R) Stent and Medtronic's Endeavor(R) Stent. In the patients with diabetes, the TAXUS Liberte Stent demonstrated a statistically significant lower restenosis rate compared to the Endeavor Stent, which had more than two times the risk of repeat procedures.
The Swedish Coronary Angiography and Angioplasty Registry holds data on all patients undergoing PCI in Sweden. The objective of this independent study was to evaluate restenosis rates of drug-eluting stents in patients with and without diabetes in a real-world setting. The JACC article reported that both the TAXUS Liberte Stent and Boston Scientific's first-generation DES -- the TAXUS(R) Express(R) Stent -- were the only stents in the study showing no increased risk of restenosis for patients with diabetes as compared to those without diabetes. Both the Cypher Stent and Endeavor Stent showed significant increased risk of restenosis in patients with diabetes. In addition, the study showed that the TAXUS Liberte Stent had an approximately 23 percent lower restenosis rate at two years compared to the prior-generation TAXUS Express Stent. The authors concluded that "There seem to be important differences between different brands of DES."(1)
"The results of this study are noteworthy for TAXUS Liberte, which compared favorably in rates of repeat procedures to both 'olimus stents," said Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "The findings presented in the article are consistent with our own clinical trial observations, including recently published ARRIVE and ATLAS data, and may reflect the different mechanism of action for paclitaxel compared to the 'olimus agents used in the other drug-eluting stents. The newer and thinner-strut TAXUS Liberte Stent performed better than the TAXUS Express Stent in reducing restenosis."
The Swedish registry study included four DES brands: TAXUS Liberte, TAXUS Express, Cypher and Endeavor. In total, the registry included 35,478 DES implants during 22,962 procedures in 19,004 patients, with 1,807 restenoses reported over a mean 29-month follow-up period. For the entire study population, the repeat revascularization rate per stent was 3.5 percent after one year and 4.9 percent after two years. Overall, the adjusted risk of restenosis was 1.23 times higher in patients with diabetes than in patients without diabetes. In patients with diabetes, restenosis was higher in the non-TAXUS Stents. The sirolimus-eluting Cypher Stent and the zotorolimus-eluting Endeavor Stent had higher restenosis rates in patients with diabetes compared with those in patients without diabetes (1.25 times and 1.77 times, respectively).
TAXUS Stents have been evaluated by the industry's most extensive randomized, controlled clinical trial program, with follow-up to five years in some cases. These trial results have been supplemented by data on more than 35,000 patients enrolled in post-approval registries. To date, approximately 11 million Boston Scientific stents have been implanted globally, making them the world's most frequently used stents.
The TAXUS Liberte Paclitaxel-Eluting Coronary Stent System received U.S. Food and Drug Administration approval in October 2008, and received European CE Mark approval for use in patients with diabetes in December 2007. In the U.S., the TAXUS Stents are not specifically indicated for use in patients with diabetes.
(1) J Am Coll Cardiol 2009;53:1660-7 Forward Looking Statements --------------------------
Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2009 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research, development, product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand manufacturing and commercialization activities or consummate acquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments. (C) 2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved. About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech , please visit our website at http://www.angiotech.com/.
Angiotech Pharmaceuticals, Inc.
CONTACT: DeDe Sheel, Investor Relations and Corporate Communications,
Angiotech Pharmaceuticals, Inc., (415) 293-4412,
dede.sheel@fdashtonpartners.com
?? is there something in the pipe ??
again! - why this rise (without news) ??
why this rise (without news) ??
NACEL Energy and the American Recovery and Reinvestment Act of 2009
* On Wednesday March 11, 2009, 7:30 am EDT
http://finance.yahoo.com/news/NACEL-Energy-and-the-American-prnews-14602346.html?.v=1
DENVER, March 11 /PRNewswire-FirstCall/ -- NACEL Energy Corporation (OTC Bulletin Board: NCEN - News; FRANKFURT: "4FC") ("NACEL Energy" or "Company"), a wind power company in business to generate clean, renewable energy, today provided guidance to shareholders and interested parties, concerning the impact of the American Recovery and Reinvestment Act of 2009 (the "Stimulus Legislation"), signed into law by President Obama in Denver, Colorado on February 25, 2009, on the Company's Blue Creek, Channing Flats, Swisher and Hedley Pointe wind power projects, all underway in the Texas Panhandle, as well as the Company's pipeline of new wind projects in feasibility, in three other States.
Under present Federal law, an income tax credit of 2.1 cents/kilowatt-hour, indexed for inflation, exists for the production of electricity from utility class wind turbines. This incentive, termed the renewable energy production tax credit (PTC), was created under the Energy Policy Act of 1992. The Stimulus Legislation includes a three-year extension of the PTC. Consequently, the 2.1 cents/kilowatt-hour tax credit may be applied to all NACEL Energy's existing and proposed wind power generation projects, through the new expiration date of December 31, 2012.
However, NACEL Energy believes that the most important aspect of the Stimulus Legislation is the new option to elect a 30% investment tax credit (ITC), up front, in lieu of the PTC. This option is available to NACEL Energy for all wind power generation facilities which it places in service in 2010, and also for facilities placed in service before 2013, if construction begins before the end of 2010.
Further, the Stimulus Legislation also allows NACEL Energy, in lieu of the PTC or the ITC, to elect to receive a direct grant from the Department of Treasury equal in amount to the ITC, being 30% of the construction cost of the applicable wind project. The Department of Treasury is required to pay the grant request within 60 days of the later of (i) the date of the Company's application which must be received before October 1, 2011, or (ii) the date that the specified Company wind facility commences commercial operations.
NACEL Energy Chief Executive Officer, Brian Lavery, stated:
"The impact of the American Recovery and Reinvestment Act on NACEL Energy's expected cash flow from our four Texas projects, now underway, is extremely positive. The Company will additionally endeavor to advance our three wind project opportunities in feasibility, in order to fully capitalize on the provisions of this new legislation."
schitteböhn!
IMO - ASYTQ not bottomed yet...
LINK added to ibox!
Stockupticks.com (May 5th, 2009)
http://www.stockupticks.com/profiles/5-5-09.html
LIZ ?? Thought, opinions, ideas ??
http://finance.yahoo.com/q/pr?s=liz
Liz Claiborne, Inc., through its subsidiaries, engages in the design and marketing of a range of apparel and accessories worldwide. It offers womens, mens, and childrens contemporary apparel, denim and casual sportswear, intimate apparel, classic career and casual apparel for women, and activewear. The company also provides various accessories, including jewelry, handbags, and fragrances, as well as bath and body-care products. Liz Claiborne offers its products under the primary brands, including KATE SPADE, JUICY COUTURE, LUCKY BRAND JEANS, and MEXX. In addition, it sells its products under its wholesale-based brands comprising AXCESS, CLAIBORNE, CONCEPTS BY CLAIBORNE, DANA BUCHMAN, ENYCE, KENSIE, LIZ & CO., LIZ CLAIBORNE, MAC & JAC, MARVELLA, MONET, NARCISO RODRIGUEZ, TRIFARI, and VILLAGER; licensed brands, such as DKNY JEANS and DKNY ACTIVE; and non-direct fragrance brands, including CLAIBORNE, CURVE, LIZ CLAIBORNE, and USHER. As of January 3, 2009, the company operated a total of 443 specialty retail stores, including 291 in the United States and 152 primarily in western Europe and Canada; and 365 outlet stores comprising 212 in the United States and 153 primarily in western Europe and Canada. It also engages in e-commerce and licensing operations relating to its various retail and wholesale brands. The company was founded in 1976 and is based in New York, New York.
CROX ?? Thought, opinions, ideas ??
http://finance.yahoo.com/q/pr?s=CROX
Crocs, Inc. and its subsidiaries design, develop, and manufacture consumer products from specialty resins worldwide. It primarily offers footwear for men, women, and children under the Crocs brand. The company designs and sells a range of footwear, apparel, gear, and accessories that utilize its proprietary closed cell-resin, called Croslite. It also offers a line of apparel for boys, girls, and men featuring Croslite material; and accessories, including snap-on charms, backpacks, and messenger bags. Crocs sells its products through crocs branded retail store locations, including company-operated kiosks and retail stores; Web stores; sporting goods and department stores; specialty retailers; and sales agents and buying groups. As of December 31, 2008, it operated 70 domestic and international retail stores, 174 domestic and international retail kiosks located in malls and other high foot traffic areas, and 32 outlet stores. The company was formerly known as Western Brands, LLC and changed its name to Crocs, Inc. in January 2005. Crocs, Inc. was founded in 1999 and is based in Niwot, Colorado
ANN ?? Thought, opinions, ideas ??
http://finance.yahoo.com/q/pr?s=ANN
AnnTaylor Stores Corporation, through its subsidiaries, operates as a specialty retailer of women's apparel, shoes, and accessories under the Ann Taylor, LOFT, Ann Taylor Factory, and LOFT Outlet brands in the United States. Its stores offer a range of career and casual separates, dresses, tops, weekend wear, shoes, and accessories. The company serves customers through its traditional retail stores and on the Internet at anntaylor.com and anntaylorLOFT.com, as well as by phone. As of January 31, 2009, it operated 935 retail stores, including 320 Ann Taylor stores, 510 LOFT stores, 91 Ann Taylor Factory stores, and 14 LOFT Outlet stores in 46 states, the District of Columbia, and Puerto Rico. The company was founded in 1986 and is headquartered in New York, New York.
Banks Won Concessions on Tests
MAY 9, 2009
http://online.wsj.com/article/SB124182311010302297.html#project%3DSTRESSTESTDOCS0905%26articleTabs%3Darticle